Please login to the form below

Not currently logged in
Email:
Password:

Hutchison China Medipharma signs research agreement with Eli Lilly

China-headquartered pharmaceutical company, Hutchison China Meditech, has revealed that its Hutchison MediPharma (HMPL) unit agreed a research collaboration with US-based Eli Lilly to co-develop oncology and anti-inflammatory medicines.

China-headquartered pharmaceutical company, Hutchison China Meditech, has revealed that its Hutchison MediPharma (HMPL) unit agreed a research collaboration with US-based Eli Lilly to co-develop oncology and anti-inflammatory medicines.

Hutchison will be awarded milestone payments of between USD 20m and USD 29m according to the type of clinical candidate. The company will also receive an upfront fee, annual R&D support costs, as well as also potential royalties.

Per the agreement, Hutchison will take responsibility for initial R&D, while Eli Lilly will offer technological advice and clinical trial expertise as the project develops.

Hutchison said that the research will be based in China to reduce overall costs.

In July 2007, Lilly revealed that the Oncologic Drugs Advisory Committee of the FDA had voted to recommend approval of its osteoporosis drug Evista (raloxifene) for a new use to reduce invasive breast cancer risk in post-menopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.

Lilly's cancer pipeline includes enzastaurin for brain cancer, which it intends to submit to the FDA in 2008, as well as arzoxifene for osteoporosis and prevention of breast cancer for submission in 2009.

HMPL currently has clinical programmes in preclinical and discovery stages to study its leading oncology candidate, a radio sensitiser, in multiple types of cancers, including non-small cell lung cancer (NSCLC) and head and neck cancer. The company's discovery research is focused on specific oncological and haematological targets with a full panel of in-vitro and in-vivo assays.

2nd September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics